Trinity Biotech Appoints Chief Commercial Officer

Adrian Donohue has been named chief commercial officer at Trinity Biotech. 

“We are resolute in continuing to execute on our transformation agenda, which will drive greater performance and profitability in our existing product lines, including supporting continued growth in our newest rapid HIV testing product, TrinScreen HIV,” Trinity Biotech President/CEO John Gillard said. “Adrian’s appointment to this important leadership role and responsibility for our entire portfolio is a critical step to achieve this commitment and we are delighted to have him join the team.”
  
Throughout this career Donohue developed a strong reputation as a successful sales and marketing executive with keen business and commercial acumen, particularly with regard to successful launches of life science products in Europe, the Middle East, Africa, and more recently Japan. Donohue is known as an effective team builder and leader, through his natural engagement and influencing skills, according to Trinity Biotech executives. He has a passion for innovation and cutting-edge development and his collaborative style facilitates a productive working culture. These strengths combine with a fresh and innovative approach to developing and delivering on commercial strategies.
 
Donohue has more than 25 years of experience in selling and marketing healthcare products. He developed his knowledge and early career success as a sales representative for Menarini, Eli Lilly, and Roche. Donohue then broadened his commercial experience as senior brand manager at Shire Pharma for six years before heading the EMEA Franchise at Biomarin for nearly a decade, the latter of which led to his promotion to global senior director in 2022.

Donohue earned a primary degree from the University College Dublin and a graduate degree in entrepreneurial studies from the Smurfit School of Business.

“It’s an exciting time to be joining Trinity Biotech as it executes on a comprehensive transformation plan and positions itself to be a global competitor in the continuous glucose monitor (CGM) market,” Donohue stated. “I look forward to driving the potential of our range of products to deliver benefits to our customers and the patients they serve. I am also eager to begin preparations for the international launch of our CGM.”
 
Trinity Biotech is a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. It has recently entered the wearable biosensor industry via the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Trinity Biotech’s products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma, and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in more than 75 countries worldwide.